Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.
Previous findings have indicated that the major surface molecule of Leishmania, lipophosphoglycan (LPG), could abrogate HIV-1-induced syncytium formation and virus replication. In the present work, we were interested in characterizing this inhibitory process. Data from a new luciferase-based semiquantitative assay for syncytium formation, relying on the coincubation of a T-cell line containing an HIV-1 LTR-driven luciferase construct with a cell line chronically infected with HIV-1, confirmed that LPG was indeed a strong inhibitor of HIV-1-dependent syncytium formation and that this inhibition was dose-dependent. As determined by flow cytometric analyses, this inhibition was not apparently due to downregulation of CD4, CXCR4 or LFA-1, three distinct surface glycoproteins known to be important in HIV-1 mediated syncytium formation. Furthermore, LPG did not seem to affect signal transduction pathways in T cells as judged by measurement of HIV-1 LTR-driven reporter gene activity upon treatment with different stimuli. However, pretreatment of either of the cell lines used in the assay with LPG led to a significant decrease of virus-mediated syncytium formation, which was further accentuated when both cell lines were pretreated. LPG inhibition of HIV-1 replication was next assessed. When measuring either infection with luciferase-encoding recombinant HIV-1 particles or multinucleated giant cell formation following an acute virus infection, we again observed that LPG was efficient at blocking HIV-1 replication. Specific assays probing different steps of viral entry demonstrated that attachment was not hindered by LPG but that viral entry was modulated, suggesting that LPG targets a postbinding step. Hence, incorporation of LPG into a target cell membrane could influence its fluidity and diminish both the virus-cell and cell-to-cell fusion processes initiated by HIV-1.
Genois
N
N
Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Canada.
Barbeau
B
B
Olivier
M
M
Tremblay
M J
MJ
D000818:Animals; D019380:Anti-HIV Agents / Q000302:isolation & purification / Q000494:pharmacology*; D015704:CD4 Antigens / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology; D002460:Cell Line / Q000187:drug effects; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects; D017930:Genes, Reporter; D015726:Giant Cells; D006028:Glycosphingolipids / Q000302:isolation & purification / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D019169:Jurkat Cells / Q000187:drug effects / Q000821:virology; D007893:Leishmania donovani / Q000737:chemistry*; D008156:Luciferases / Q000032:analysis; D016169:Lymphocyte Function-Associated Antigen-1 / Q000096:biosynthesis; D008561:Membrane Fusion / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000096:biosynthesis; D015398:Signal Transduction / Q000187:drug effects; D014162:Transfection; D014779:Virus Replication / Q000187:drug effects*
D019380:Anti-HIV Agents; D015704:CD4 Antigens; D006028:Glycosphingolipids; D016169:Lymphocyte Function-Associated Antigen-1; D019718:Receptors, CXCR4; C008290:lipophosphonoglycan; D008156:Luciferases